{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T09:06:41Z","timestamp":1793869601737,"version":"4.6.1"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018525","name":"Key Research and Development Program of Sichuan Province","doi-asserted-by":"publisher","award":["2020YFS0273, 2023YFS0171"],"award-info":[{"award-number":["2020YFS0273, 2023YFS0171"]}],"id":[{"id":"10.13039\/501100018525","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Circadian rhythms in the immune system and anti-tumor responses are underexplored in cancer immunotherapy. Despite the success of immune checkpoint inhibitors (ICIs) in treating advanced biliary tract cancers (BTCs), not all patients benefit. This study examined whether the timing of ICI administration affects outcomes in advanced BTC patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We included advanced BTC patients from West China Hospital of Sichuan University who received \u22652 ICI treatments from October 2019 to September 2023, with follow-up until May 2024. Primary outcome was overall survival (OS), with secondary outcomes including progression-free survival (PFS), objective response rate (ORR), and adverse events (AEs). Propensity score matching (1:2 ratio, caliper width 0.1) mitigated confounding factors. Cox proportional hazards regression analyzed the impact of ICI timing (post-16:30) on OS and PFS. Chi-square test assessed ORR and AE differences.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 221 patients, 51 received \u226520% of ICIs after 16:30; 170 received &amp;lt;20%. Post-matching, 49 late-infusion patients had significantly shorter OS (median 10.1 <jats:italic>vs<\/jats:italic>. 14.5 months, HR=1.80, P=0.012) compared to 90 early-infusion patients. Pre-matching, late-infusion patients also had shorter OS (median 9.8 <jats:italic>vs<\/jats:italic>. 13.7 months, HR=1.68, P=0.010) and PFS (median 4.9 <jats:italic>vs<\/jats:italic>. 8.1 months, HR=1.62, P=0.006). Multivariate analysis confirmed these results. No significant differences were found in ORR (\u03c7^2 = 1.53, P=0.215) or AEs (all P&amp;gt;0.050). Sensitivity analyses supported these findings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Timing of ICI administration affects efficacy in advanced BTC, with pre-16:30 infusions linked to better survival. Larger, prospective studies are needed to validate these results.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1512972","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T06:45:13Z","timestamp":1734504313000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Effect of immune checkpoint inhibitor time-of-day infusion on survival in advanced biliary tract cancer: a propensity score-matched analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Yichen","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanfan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingqi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonghui","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw324","article-title":"Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Valle","year":"2016","journal-title":"Ann Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30571","article-title":"A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma","volume":"123","author":"Goyal","year":"2017","journal-title":"Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet (London England)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2016.10.013","article-title":"Companion and complementary diagnostics: clinical and regulatory perspectives","volume":"2","author":"J\u00f8rgensen","year":"2016","journal-title":"Trends Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01161","article-title":"The predictive value of tumor mutation burden on efficacy of immune checkpoint inhibitors in cancers: A systematic review and meta-analysis","volume":"9","author":"Wu","year":"2019","journal-title":"Front Oncol"},{"key":"B8","article-title":"Chronopharmacology of antitumor effect induced by interferon-beta in tumor-bearing mice","volume":"294","author":"Takane","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2019.154984","article-title":"Interleukin-2 chronotherapy for metastatic renal cell carcinoma: Results of a phase I-II study","volume":"128","author":"Re","year":"2020","journal-title":"Cytokine"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00546-5","article-title":"Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study","volume":"22","author":"Qian","year":"2021","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14040896","article-title":"Time-dependent efficacy of checkpoint inhibitor nivolumab: results from a pilot study in patients with metastatic non-small-cell lung cancer","volume":"14","author":"Karabou\u00e9","year":"2022","journal-title":"Cancers"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.01.007","article-title":"Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer","volume":"182","author":"Rousseau","year":"2023","journal-title":"Eur J Cancer (Oxford England: 1990)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2023.06.004","article-title":"Association between time-of-day of immune checkpoint blockade administration and outcomes in metastatic renal cell carcinoma","volume":"21","author":"Dizman","year":"2023","journal-title":"Clin genitourinary Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.2589","article-title":"The effect of circadian rhythm on clinical outcome in patients receiving pembrolizumab in the INSPIRE pan-cancer trial","volume":"40","author":"Janse van Rensburg","year":"2022","journal-title":"Am Soc Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.1851","article-title":"A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions","volume":"33","author":"Cortellini","year":"2022","journal-title":"Ann Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.3390\/cells12162068","article-title":"Immunotherapy around the clock: impact of infusion timing on stage IV melanoma outcomes","volume":"12","author":"Gon\u00e7alves","year":"2023","journal-title":"Cells"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s10388-023-01006-y","article-title":"Timing of the infusion of nivolumab for patients with recurrent or metastatic squamous cell carcinoma of the esophagus influences its efficacy","volume":"20","author":"Nomura","year":"2023","journal-title":"Esophagus"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102220","article-title":"Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers: a study-level meta-analysis","volume":"9","author":"Landr\u00e9","year":"2024","journal-title":"ESMO Open"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.09.004","article-title":"Rational development of combination therapies for biliary tract cancers","volume":"78","author":"Harding","year":"2023","journal-title":"J Hepatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31092","article-title":"Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma","volume":"72","author":"Job","year":"2020","journal-title":"Hepatol (Baltimore Md.)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-326514","article-title":"Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications","volume":"72","author":"Martin-Serrano","year":"2023","journal-title":"Gut"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer (Oxford England: 1990)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas dermo-sifiliograficas"},{"key":"B24","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/s1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/jco.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33013","article-title":"Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies","volume":"147","author":"Piha-Paul","year":"2020","journal-title":"Int J Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0930","article-title":"A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer","volume":"6","author":"Kim","year":"2020","journal-title":"JAMA Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1162\/003465302317331982","article-title":"Propensity score-matching methods for nonexperimental causal studies","volume":"84","author":"Dehejia","year":"2002","journal-title":"Rev Economics Stat"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(00)00326-0","article-title":"Circadian chronotherapy for human cancers","volume":"2","author":"L\u00e9vi","year":"2001","journal-title":"Lancet Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25423","article-title":"Gamma knife radiosurgery for brain metastasis of nonsmall cell lung cancer: is there a difference in outcome between morning and afternoon treatment","volume":"117","author":"Rahn","year":"2011","journal-title":"Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1126\/science.3883493","article-title":"Circadian timing of cancer chemotherapy","volume":"228","author":"Hrushesky","year":"1985","journal-title":"Sci (New York N.Y.)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-015-2804-x","article-title":"Cisplatin-based chronotherapy for advanced non-small cell lung cancer patients: a randomized controlled study and its pharmacokinetics analysis","volume":"76","author":"Li","year":"2015","journal-title":"Cancer chemotherapy Pharmacol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e18016","article-title":"Chronotherapy in head and neck cancer (HNC): A systematic review","volume":"41","author":"Abu-Samak","year":"2023","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-019-03332-7","article-title":"Radiation chronotherapy-clinical impact of treatment time-of-day: a systematic review","volume":"145","author":"Shuboni-Mulligan","year":"2019","journal-title":"J neuro-oncology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.3390\/pharmaceutics15082023","article-title":"Chronotherapeutics for solid tumors","volume":"15","author":"Kisamore","year":"2023","journal-title":"Pharmaceutics"},{"key":"B36","doi-asserted-by":"publisher","first-page":"5071","DOI":"10.3390\/cancers14205071","article-title":"Chronotherapy: circadian rhythms and their influence in cancer therapy","volume":"14","author":"Amiama-Roig","year":"2022","journal-title":"Cancers"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.3390\/ijms18102168","article-title":"Molecular aspects of circadian pharmacology and relevance for cancer chronotherapy","volume":"18","author":"Ozturk","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B38","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1126\/science.aah4966","article-title":"Immunity around the clock","volume":"354","author":"Man","year":"2016","journal-title":"Sci (New York N.Y.)"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1905080116","article-title":"The circadian clock of CD8 T cells modulates their early response to vaccination and the rhythmicity of related signaling pathways","volume":"116","author":"Nobis","year":"2019","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20160723","article-title":"Adrenergic control of the adaptive immune response by diurnal lymphocyte recirculation through lymph nodes","volume":"213","author":"Suzuki","year":"2016","journal-title":"J Exp Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.12.011","article-title":"Lymphocyte circadian clocks control lymph node trafficking and adaptive immune responses","volume":"46","author":"Druzd","year":"2017","journal-title":"Immunity"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05605-0","article-title":"Dendritic cells direct circadian anti-tumour immune responses","volume":"614","author":"Wang","year":"2023","journal-title":"Nature"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1172\/jci133934","article-title":"Circadian rhythm influences induction of trained immunity by BCG vaccination","volume":"130","author":"de Bree","year":"2020","journal-title":"J Clin Invest"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.04.032","article-title":"Morning vaccination enhances antibody response over afternoon vaccination: A cluster-randomised trial","volume":"34","author":"Long","year":"2016","journal-title":"Vaccine"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13167","article-title":"Circadian rhythms in adaptive immunity","volume":"161","author":"Downton","year":"2020","journal-title":"Immunology"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-11-190769","article-title":"Cortisol and epinephrine control opposing circadian rhythms in T cell subsets","volume":"113","author":"Dimitrov","year":"2009","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.Mcr-21-0786","article-title":"Diurnal expression of PD-1 on tumor-associated macrophages underlies the dosing time-dependent antitumor effects of the PD-1\/PD-L1 inhibitor BMS-1 in B16\/BL6 melanoma-bearing mice","volume":"20","author":"Tsuruta","year":"2022","journal-title":"Mol Cancer research: MCR"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00748-2","article-title":"Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors","volume":"58","author":"Centanni","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"B49","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jconrel.2014.12.018","article-title":"Improving drug delivery to solid tumors: priming the tumor microenvironment","volume":"201","author":"Khawar","year":"2015","journal-title":"J Controlled release: Off J Controlled Release Soc"},{"key":"B50","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1084\/jem.20180870","article-title":"Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer","volume":"216","author":"Gong","year":"2019","journal-title":"J Exp Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1038\/s41467-024-48200-9","article-title":"PD-1\/CD80(+) small extracellular vesicles from immunocytes induce cold tumours featured with enhanced adaptive immunosuppression","volume":"15","author":"Zhang","year":"2024","journal-title":"Nat Commun"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02704-9","article-title":"Why does circadian timing of administration matter for immune checkpoint inhibitors\u2019 efficacy","volume":"131","author":"Karabou\u00e9","year":"2024","journal-title":"Br J Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1146\/annurev-immunol-090122-050842","article-title":"Circadian rhythms in anticancer immunity: mechanisms and treatment opportunities","volume":"42","author":"Pick","year":"2024","journal-title":"Annu Rev Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.14336\/ad.2024.0533","article-title":"Crosstalk between circadian rhythm dysregulation and tumorigenesis, tumor metabolism and tumor immune response","author":"Zhu","year":"2024","journal-title":"Aging Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1512972\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T06:45:20Z","timestamp":1734504320000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1512972\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":54,"alternative-id":["10.3389\/fimmu.2024.1512972"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1512972","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"article-number":"1512972"}}